

**Workshop**

# **Joint SEAR-WPR workshop to plan the accelerated implementation of new WHO TB policies**

**1-4  
APRIL  
2025**

**Hanoi,  
Viet Nam**

**Survey on potential benefits and  
challenges of the  
long-acting injectable medicines  
for TB treatment  
(LAIs for TB)**

**Linh Nguyen**

Medical officer, TB treatment team

WHO Global Programme on Tuberculosis &  
Lung Health



# Long-acting injectables (LAIs)

- Potential in managing various diseases or conditions
  - HIV prevention and therapy
  - Contraception
- Potential LAI formulations of multiple TB drugs to enter clinical development in the next few years (e.g. Bdq, Dlm)
  - To be used for treatment for all types of TB, DS-TB and DR-TB, or TPT
  - Potential benefits e.g. reduced dosage of medicines, and number of administered doses, which are different from old injectable agents previously used for TB treatment
- Well-defined target product/regimen profile (TPP/TRP) for LAIs is essential; and WHO is to develop an addendum to the TRPs

# Survey

## **Objectives:**

- to provide insights into the ideal characteristics of LAIs designed to treat TB
- to guide the development of LAI therapies to ensure they meet the needs of patients, healthcare providers and systems

## **Questionnaire:**

- 11 questions
- Time to complete: ~ 10 minutes


## **Ethics approval:**

- ERCs of WHO SEARO and WPRO

# Core concepts


## 1. Co-formulation of medications

- Oral TB medications have been co-formulated to reduce pill burden, improve adherence, and assist implementation
- LAIs to be administered as multiple individual drug injections or co-formulated in a single injection



## 2. Oral lead-in

- Oral medications may be necessary during the initial treatment period. This is referred to as an “oral lead-in”



# Core concepts

## **3. Coverage duration**

- Duration of time during which the medication, after being administered as a single injection, remains effective in the body at a therapeutic level

## **4. Number of injections**

- How many injections and corresponding visits would be acceptable and feasible for patients?

## **5. Healthcare facility for LAI delivery**

- Where should LAIs be administered, at a local clinic or hospital?

## **6. Route of administration**

- Should the medications be given as an intramuscular (IM) or subcutaneous (SC) injection?

Survey on potential benefits and challenges of the  
long-acting injectable medicines for TB treatment  
(LAIs for TB)



<https://forms.gle/VuEBL4E5toeZx4py7>